VivoSeq
Hematology

Iron Deficiency Anemia

65

Pipeline Programs↗

15

Active Trials↗

21

Companies Involved↗

Iron deficiency anemia is a moderately active landscape with 65 programs across 21 companies. The most active players are Keros Therapeutics, Inc., Novartis, Zeria Pharmaceutical. 24 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

22/100

Mech. Concentration

100/100

Completion Rate

93/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Keros Therapeutics, Inc.

1 program

Phase 2Novartis logo

Novartis

2 programs

Phase 3Z

Zeria Pharmaceutical

2 programs

Phase 3A

AMAG Pharmaceuticals, Inc.

1 program

Phase 3P

Pascoe Pharmazeutische Praeparate GmbH

1 program

Phase 3N

New River Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical16

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Zinc Sulfate

Fakultas Kedokteran Universitas Indonesia

Ferrous Sulfate

Auerbach Hematology Oncology Associates P C

Riboflavin

Cornea and Laser Eye Institute

Drug

Elro Pharma

Phase 14

Daily Oral Ferrous Ion

Ain Shams University

Daily Oral Liposomal Iron

Ain Shams University

Iron Carboxymaltose

Hospital de Clinicas de Porto Alegre

Iron Salt (ferrous Fumarate)

Cairo University

Phase 24

Elemental Iron

University of Texas Southwestern Medical Center

Iron Sucrose Injection USP

Watson Pharmaceuticals

Lactoferrin and Ferrous Fumarate

Assiut University

KER-047

Keros Therapeutics, Inc.

Phase 317

Iron Sucrose

American Regent, Inc.

Iron

Watson Pharmaceuticals

Ferric Pyrophosphate Liposomal

Menoufia University

Iron Dextran

New River Pharmaceuticals

Iron Sulphate

Pierre Fabre Pharma GmbH

Approved24

Magnesium Sulfate

Fresenius Kabi Oncology Ltd.

Ferumoxytol

Azurity Pharmaceuticals

Niacin

AbbVie

Ferric Carboxymaltose

American Regent, Inc.

Lactoferrin Bovine

Al-Azhar University

Analysis

Modality Breakdown

99%

Small molecule

82 of 83 classified programs — the dominant modality here.

1%ALL OTHERSPeptide11%

Small molecule leads; the ring shows all 83 classified programs, each share of the total. Modality classified for 97% of 86 pipeline programs.

Analysis

Trial Status

87

clinical trials

Completed53 · 61%
Unknown status14 · 16%
Recruiting10 · 11%
Not yet recruiting3 · 3%
Withdrawn3 · 3%
Active, not recruiting1 · 1%
Other3 · 3%

Clinical Trials

Trial Activity

87 trials

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
Recruiting·AAuerbach Hematology Oncology Associates P C·Phase 3·NCT04268849·104 enrolled
Comparison Of Efficacy Of Iron Polymaltose Complex And Ferrous Sulphate In Iron Deficiency Anemia In Pediatric Patients
Recruiting·—·N/A·NCT06742528·198 enrolled
Oral Iron Supplementation on Alternate Vs. Consecutive Days for Iron Deficiency Anemia in Pregnancy
Recruiting·SSouthern Illinois University·Phase 4·NCT06492512·120 enrolled
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
Recruiting·AAMAG Pharmaceuticals, Inc.·Phase 3·NCT03893045·75 enrolled
Iron Deficiency Anemia (IDA) and the Brain
Recruiting·—·Phase 4·NCT05929729·120 enrolled
Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia
Recruiting·PPharmacosmos A/S·Phase 3·NCT05179226·200 enrolled
Early Antenatal Support for Iron Deficiency Anemia
Recruiting·TThomas Jefferson University·Phase 4·NCT04278651·80 enrolled
Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia
Recruiting·—·Phase 3·NCT06366698·900 enrolled
Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA)
Recruiting·PPhramongkutklao College of Medicine and Hospital·N/A·NCT07014371·114 enrolled
Comprehensive Hematological and Biochemical Comparison of Low-Dose Liposomal Iron Versus Standard-Dose Conventional Oral Iron in Iron Deficiency Anemia Following Sleeve Gastrectomy: A Prospective, Randomized Clinical Trial
Recruiting·—·Preclinical·NCT07366502·70 enrolled
Daily Versus Alternate Day Regimen of Iron Supplementation in Children with Iron Deficiency Anemia
Active, not recruiting·—·Phase 4·NCT06631612·72 enrolled
The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department
Not yet recruiting·—·Phase 4·NCT07414199·150 enrolled
Ferric Citrate in Iron Deficiency Anemia During Pregnancy
Not yet recruiting·—·Phase 3·NCT07381426·680 enrolled
A Randomized Controlled Trial Comparing Daily Oral Iron Administration to Every Alternate Day Iron Administration in the Treatment of Iron Deficiency Anemia in Pediatric Patients.
Not yet recruiting·LLoma Linda University·Approved·NCT06550362·100 enrolled
Liposomal Iron Versus Ferrous Iron Supplementation for Early Prophylaxis of Iron Deficiency Anemia in Preterm Neonates
Enrolling by invitation·AAin Shams University·Phase 1·NCT07667205·60 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)